{"description":"Documents matching 'semaglutide'","count":14,"total_pages":1,"results":[{"title":"Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"},{"title":"List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act"},{"title":"List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period"},{"title":"Jeremy Spencer Brown: Final Debarment Order"},{"title":"Product-Specific Guidances; Revised Draft Guidances for Industry; Availability"},{"title":"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability"},{"title":"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability"},{"title":"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability"},{"title":"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability"},{"title":"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability"},{"title":"Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly"},{"title":"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability"},{"title":"Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC"},{"title":"Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments"}]}